GeoVax Labs, Inc.
- Open
- 0.66
- Day high
- 0.68
- Day low
- 0.59
- Prev close
- 0.72
- Volume
- 635K
- Mkt cap
- $5M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.6
- P/S
- —
- Yield
- —
- Per share
- —
GeoVax Labs, Inc. (GOVX) is a Healthcare company listed on NASDAQ. The stock is down 97% over the past year. Drillr has 1 published research article covering GOVX.
GeoVax Labs, Inc. (GOVX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GOVX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 27, 2026 | $-2.16 | $-0.97 | +55.1% | — | — |
| May 14, 2026 | $-1.60 | $-2.62 | -63.7% | — | — |
| Nov 13, 2025 | $-6.00 | $-7.75 | -29.2% | — | — |
| May 1, 2025 | $-0.59 | $-0.45 | +23.7% | $2M | +346.4% |
| Mar 27, 2025 | $-0.79 | $-0.30 | +62.0% | $864415 | -63.7% |
| Feb 29, 2024 | $-2.78 | $-13.60 | -389.2% | — | — |
| May 4, 2023 | $-2.85 | $-2.25 | +21.1% | — | — |
| Mar 8, 2023 | $-0.20 | $-2.24 | -1020.0% | — | — |
| Nov 9, 2022 | $-1.80 | $-2.55 | -41.7% | — | — |
| Aug 3, 2022 | $-0.32 | $-2.70 | -743.8% | — | — |
| Mar 9, 2022 | $-0.40 | $-33.58 | -8295.0% | $164962 | — |
| Nov 11, 2021 | $-0.37 | $-4.65 | -1156.8% | $30414 | — |
GOVX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 22, 2026 | Reynolds Markofficer: CFO | Grant | 17,600 | $1.18 |
| Jun 22, 2026 | CHASE RANDAL Ddirector | Grant | 6,000 | $1.18 |
| Jun 22, 2026 | Kollintzas Dean Gdirector | Grant | 6,000 | $1.18 |
| Jun 22, 2026 | Lemerond Nicoledirector | Grant | 6,000 | $1.18 |
| Jun 22, 2026 | MCNALLY ROBERT Tdirector | Grant | 6,000 | $1.18 |
| Jun 22, 2026 | Morgan Jaynedirector | Grant | 6,000 | $1.18 |
| Jun 22, 2026 | SPENCER JOHN N JRdirector | Grant | 6,000 | $1.18 |
| Jun 22, 2026 | Sharkey John W.officer: VP, Business Development | Grant | 17,600 | $1.18 |
| Jun 22, 2026 | DODD DAVID Adirector, officer: President, CEO | Grant | 29,300 | $1.18 |
| Jun 22, 2026 | McKee Kelly T. Jr.officer: Chief Medical Officer | Grant | 17,600 | $1.18 |
| Jun 22, 2026 | NEWMAN MARK Jofficer: Chief Scientific Officer | Grant | 17,600 | $1.18 |
| Aug 8, 2025 | McKee Kelly T. Jr.officer: Chief Medical Officer | Buy | 1,107 | $0.67 |
| Jun 6, 2025 | Morgan Jaynedirector | Grant | 10,000 | $2.48 |
| Jun 6, 2025 | MCNALLY ROBERT Tdirector | Grant | 10,000 | $2.48 |
| Jun 6, 2025 | Kollintzas Dean Gdirector | Grant | 10,000 | $2.48 |
Source: GOVX SEC Form 4 filings, latest Jun 22, 2026. For informational purposes only — not investment advice.
See the full GOVX insider & 13F page →GeoVax Labs, Inc. company profile
Overview
GeoVax Labs, Inc. (NASDAQ:GOVX) is a clinical-stage biotechnology company founded in 1988 and headquartered in Smyrna, Georgia. The company went public in September 2020 and specializes in developing human vaccines and immunotherapies against infectious diseases and cancers using its proprietary modified vaccinia ankara virus-like particle (MVA-VLP) vaccine platform. GeoVax has established strategic partnerships with prestigious institutions including the National Institutes of Health, Centers for Disease Control and Prevention, U.S. Department of Defense, Emory University, University of Pittsburgh, and the Burnet Institute. The company has evolved from its early research focus to become a clinical-stage developer with multiple vaccine candidates in various phases of development.
Business
GeoVax operates in the biotechnology sector, specifically focusing on vaccine development and immunotherapy. The company's core technology platform is based on Modified Vaccinia Ankara Virus-Like Particles (MVA-VLP), which is a sophisticated vaccine delivery system that combines the safety profile of MVA vectors with the immunogenic properties of virus-like particles. The MVA platform is particularly significant because it represents a proven, safe vaccine technology that has been used in humans for decades. MVA is a highly attenuated strain of vaccinia virus that cannot replicate in human cells, making it exceptionally safe even for immunocompromised patients. When combined with virus-like particles, this platform can stimulate both antibody and cellular immune responses, potentially providing broader and more durable protection than traditional vaccines. GeoVax's product pipeline spans three main therapeutic areas: 1. **Infectious Disease Vaccines** (~80% of development focus): The company is developing preventive vaccines against COVID-19 (GEO-CM04S1), HIV, Zika virus, malaria, and hemorrhagic fever viruses including Ebola, Sudan, Marburg, and Lassa. Their COVID-19 vaccine specifically targets immunocompromised populations and aims to provide broader variant protection. The company is also developing GEO-MVA, a vaccine against mpox (monkeypox) and smallpox, positioning itself to become the first U.S.-based supplier of MVA vaccines. 2. **Therapeutic Vaccines** (~15% of development focus): These include therapeutic interventions for chronic Hepatitis B infections and HIV, designed to boost immune responses in patients already infected with these viruses. 3. **Cancer Immunotherapy** (~5% of development focus): The company's lead oncology candidate is Gedeptin, a therapeutic vaccine for solid tumor cancers, particularly head and neck squamous cell carcinomas. This represents a novel approach to cancer treatment by stimulating the patient's immune system to recognize and attack cancer cells.
Revenue model
GeoVax generates revenue primarily through government contracts and grants, particularly from agencies like the Biomedical Advanced Research and Development Authority (BARDA). In 2024, the company received approximately $4 million in BARDA contract revenue, representing a significant increase from zero revenue in 2023. The company was awarded a substantial BARDA Project NextGen contract valued at almost $400 million for its COVID-19 vaccine development, though this funding was later subject to a stop work order. The company's business model is typical of clinical-stage biotechnology firms, relying on government funding, strategic partnerships, and eventual product commercialization. Revenue streams include research and development contracts, milestone payments from partnerships, and future product sales upon regulatory approval. The paying customers are primarily government agencies, healthcare systems, and potentially international health organizations for vaccines addressing global health needs. Several factors significantly impact GeoVax's margins and financial performance. Positive margin drivers include the company's focus on underserved patient populations (particularly immunocompromised individuals) where premium pricing may be justified, the potential for expedited regulatory pathways due to unmet medical needs, and the scalability of the MVA platform across multiple indications. The company's partnership strategy also helps share development costs and risks. Negative margin pressures include the inherently high costs and lengthy timelines of clinical development, particularly for vaccines which require large patient populations and long-term safety monitoring. The company faces intense competition from established pharmaceutical giants with greater resources, regulatory uncertainties that can impact funding and development timelines, and the challenge of manufacturing complex biological products at scale. Additionally, the company's dependence on government funding creates vulnerability to policy changes and budget constraints, as evidenced by the recent BARDA stop work order.
Competitive moat
GeoVax's competitive moat is relatively narrow but has some distinctive elements. The company's primary competitive advantage lies in its specialized MVA-VLP platform technology and its focus on underserved patient populations, particularly immunocompromised individuals who respond poorly to conventional vaccines. The MVA platform's exceptional safety profile, especially for immunocompromised patients, provides a meaningful differentiation in a market where safety is paramount. The company has built valuable relationships with prestigious government agencies and academic institutions, creating a network effect that facilitates funding and collaboration opportunities. Their expertise in navigating regulatory pathways for vaccines, combined with their established manufacturing processes, represents accumulated institutional knowledge that would be difficult for new entrants to replicate quickly. However, GeoVax's moat is not particularly strong when viewed objectively. The biotechnology sector is characterized by rapid technological advancement, and larger pharmaceutical companies possess significantly greater resources for research, development, and commercialization. Major players like Pfizer, Moderna, and Johnson & Johnson have demonstrated their ability to rapidly develop and deploy vaccines at global scale, as evidenced during the COVID-19 pandemic. The company faces substantial competitive threats from established vaccine manufacturers who could potentially develop competing products for immunocompromised populations, well-funded biotech competitors with similar or superior platform technologies, and the constant risk of technological obsolescence as new vaccine platforms emerge. Additionally, the company's dependence on government funding makes it vulnerable to policy shifts and budget reallocations that could favor larger, more established contractors.
Risks & safety
GeoVax presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with both strengths and significant risks. **Overall Assessment**: Moderate to high financial risk due to cash burn and pre-revenue status, but reasonable near-term liquidity position. • **Cash and Liquidity**: $7.4 million cash as of Q1 2025, down from $8.6 million in Q3 2024, indicating ongoing cash consumption • **Burn Rate**: Quarterly cash burn of approximately $6 million based on operating cash flows, providing roughly 3-4 quarters of runway at current burn rate • **Debt Position**: Zero debt, eliminating solvency risk from leverage • **Current Ratio**: Strong at 3.6x, indicating good short-term liquidity management **Valuation Metrics**: • **Price-to-Book**: 1.6x, reasonable for a biotech company with tangible assets • **Enterprise Value**: Minimal given cash position and low market cap • **Revenue Multiple**: Not meaningful given minimal revenue base **Other Considerations**: • **Funding Dependency**: High reliance on government contracts and grants creates revenue volatility • **Clinical Risk**: Multiple Phase 2 trials ongoing with binary outcomes that could significantly impact valuation • **Regulatory Risk**: Vaccine development subject to extensive regulatory oversight with uncertain timelines
Recent development
Over the past few years, GeoVax has undergone significant strategic evolution, transitioning from a research-focused organization to a clinical-stage company with multiple active programs. The most significant development was securing the BARDA Project NextGen contract worth almost $400 million for COVID-19 vaccine development, though this was subsequently subject to a stop work order with estimated annual impact of less than $750,000. The company has strategically pivoted to focus heavily on immunocompromised patient populations, recognizing this as an underserved market with significant unmet medical need. This focus is evident across their COVID-19 vaccine program, where they are conducting three Phase 2 clinical trials specifically targeting patients with conditions like chronic lymphocytic leukemia (CLL) who respond poorly to conventional vaccines. GeoVax has also expanded its manufacturing capabilities, completing cGMP (current Good Manufacturing Practice) production of clinical batches for both their COVID-19 and mpox vaccines. The company is positioning itself to become the first U.S.-based supplier of MVA vaccines, addressing national security concerns about vaccine supply chain independence. In oncology, the company has advanced Gedeptin through Phase I/II trials for head and neck cancer and is preparing for expanded Phase II trials. They are exploring combination therapies with immune checkpoint inhibitors, reflecting the industry trend toward combination immunotherapy approaches. The company has strengthened its partnerships and collaborations, engaging with international organizations like the World Health Organization and Africa CDC for mpox vaccine development, while maintaining strong relationships with U.S. government agencies and academic institutions.
GOVX company profile · for informational purposes only — not investment advice.
Track GOVX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free